Argolyn Bioscience, Inc. Seeks $10 Million

DURHAM – Argolyn Bioscience is targeting a financing round in the neighborhood of $10 million that would provide the funding needed to start human trials on the company’s lead product, a pain medication based on amino acid chains called peptides.